Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL9 | O00512 | 4/20 | 0.55 |
| ▸ | CTNNB1 | P35222 | 4/20 | 0.55 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.49 |
| ▸ | PPARD | Q03181 | 2/20 | 0.48 |
| ▸ | RARG | P13631 | 6/20 | 0.47 |
| ▸ | RARB | P10826 | 6/20 | 0.47 |
| ▸ | RARA | P10276 | 4/20 | 0.47 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.45 |
| ▸ | THRA | P10827 | 1/20 | 0.45 |
| ▸ | THRB | P10828 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18165178 | 0.89 | RARB (0.59) | BCL9CTNNB1PTPN11PPARDRARG | |
| SCHEMBL20021935 | 0.88 | BCL9 (0.55) | BCL9CTNNB1PPARD | |
| SCHEMBL20021933 | 0.87 | BCL9 (0.53) | BCL9CTNNB1PTPN11PPARDRARG | |
| SCHEMBL14142916 | 0.85 | PPARD (0.48) | PTPN11PPARDRARGRARBRARA | |
| SCHEMBL18152321 | 0.82 | PTGER1 (0.58) | BCL9CTNNB1RARGPTGER1 | |
| SCHEMBL1470380 | 0.81 | LMNA (0.63) | PTPN11THRATHRBKMT2A | |
| SCHEMBL13535958 | 0.81 | TTR (0.57) | PTPN11KMT2A | |
| SCHEMBL20021941 | 0.80 | CTNNB1 (0.86) | BCL9CTNNB1 | |
| SCHEMBL18152551 | 0.80 | BCL9 (0.48) | BCL9CTNNB1PPARDRARGRARB | |
| SCHEMBL4601436 | 0.80 | PTPN11 (0.59) | PTPN11PPARDRARGRARBRARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180092866-A1 | SUBSTITUTED N-([1,1'-BIPHENYL]-3-YL)-[1,1'-BIPHENYL]-3-CARBOXAMIDE ANALOGS AS INHIBITORS FOR BETA-CATENIN/B-CELL LYMPHOMA 9 INTERACTIONS | THE GOVERNMENT OF THE UNITED STATES, AS REPRESENTED BY THE SECRETARY OF THE ARMY | 2018-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180092866-A1 | SUBSTITUTED N-([1,1'-BIPHENYL]-3-YL)-[1,1'-BIPHENYL]-3-CARBOXAMIDE ANALOGS AS INHIBITORS FOR BETA-CATENIN/B-CELL LYMPHOMA 9 INTERACTIONS | BCL9, BCL9L, BCL3 | BCL9 1/4885CTNNB1 4/4885PTPN11 3108/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.